Home

Applications

APPLICATIONS OVERVIEW
DRUG DISCOVERY
ADME-Tox
Biochemical Assays
Cell-based Assays
HTS and Secondary Screening
Microsampling
Protein Crystallography
RNAi
Sample Management
CANCER RESEARCH
Personalized Medicine
Functional Screening / DSRT
RNAi
Sequencing
Single-cell Genomics
GENOMIC RESEARCH
Gene Expression
Genotyping
Microbiome
qPCR
Sequencing
Single-cell Genomics
Synthetic Biology

Products

LIQUID HANDLING
LIQUID HANDLERS OVERVIEW
Echo® 525 Liquid Handler
Echo® 555 Liquid Handler
Echo® 550 Liquid Handler
Echo® 520 Liquid Handler
AUTOMATION
AUTOMATION OVERVIEW
Access™ Laboratory Workstation
Tempo™ Automation Control Software
SOFTWARE APPLICATIONS
SOFTWARE OVERVIEW
Echo® Array Maker
Echo® Cherry Pick
Echo® Combination Screen
Echo® Compliance Manager
Echo® Dose-Response
Echo® Plate Audit
Echo® Plate Reformat
CONSUMABLES
CONSUMABLES OVERVIEW
Echo® Qualified Microplates
Labcyte® Assay Microplates
MicroClime® Environmental Lid
Echo® Qualified Reservoir

Technology

Echo® Acoustic Liquid Handling
Dynamic Fluid Analysis™
Acoustic Mass Spectrometry
Direct Dilution

News / Events

Labcyte BLOG
Upcoming Events
Press Releases
Labcyte in the News
Labcyte Community

Resources

JALA Special Issue
Publications
Articles and Other Media
Application Notes
Posters
Webinars
Videos
Customer Profiles
Core Labs

Support

Brochures
Web Documentation*
User Guides*
Quick Start Guides*
Specification Sheets
Site Prep Guides
Service and Maintenance
Request Information

Company

About Us
Echo® Acoustic Technology
Leadership Team
Meet Labcyte
Careers
Contact and Location
Privacy Policy

Labcyte BLOG

Precision at the Heart of Precision Oncology
THURSDAY, NOVEMBER 30, 2017
linkedin twitter facebook |  2Shares

The future of precision oncology is happening now, in the labs of Seattle-based start-up SEngine, where individual patient tumor cells are screened against a library of nearly 150 drugs to find the optimal personalized treatment.


As CEO Carla Grandori, M.D., Ph.D., tells Theral Timpson in this episode of Mendelspod, the CLIA-certified PARIS test would not be possible without recent advances in technology that allow for true precision and miniaturization.


Grandori credits “the perfection of robotics,” and mentions Labcyte technology in particular.


“The latest example is a sound-driven instrument called the Echo from Labcyte, which is able to really eject microdops highly accurately onto cells,” Grandori says. “We didn’t have instruments like this... widely used and widely available in settings other than industry before, and they were really used mostly to do biochemical assays, not for cells.”


The technology may also provide opportunities to improve the process even further.


Grandori says it can be challenging to collect adequate sample sizes in solid tumors. Her test currently requires 2 million cells, an amount that about fits on the cap of a pen. It may seem small, but it’s still a lot, especially when considering cancer cells are usually the minority of cells collected in a biopsy, and that the samples often include extraneous stromal tissue, she adds.


“We’re looking to make the assay even smaller and miniaturized, where we would need less,” Grandori says.


Listen now, and learn more about SEngine’s use of Labcyte technology in this customer profile.